Alexandre V. Hirayama, MD

Faculty Member

Alexandre V. Hirayama, MD

Assistant Professor
Clinical Research Division, Fred Hutch

Member
Immunotherapy Integrated Research Center (IIRC), Fred Hutch

Mail Stop: D3-100

Dr. Alexandre V. Hirayama is a hematologist-oncologist specializing in the care of patients with blood cancers undergoing blood and marrow transplantation and cellular immunotherapies. Much of his focus is on chimeric antigen receptor T-cell therapy (or CAR T-cell therapy), a cutting-edge treatment involving the transfer of engineered disease-fighting immune cells into a patient. Dr. Hirayama leverages state-of-the-art technologies to gain a comprehensive understanding of the factors impacting outcomes following these immunotherapies. Through his work, he aims to design and conduct clinical trials to hasten the development of more effective immunotherapies, ultimately improving patient outcomes.

Other Appointments & Affiliations

Affiliate Investigator
Translational Science and Therapeutics Division, Fred Hutch

Assistant Professor, Division of Hematology and Oncology
University of Washington School of Medicine

Education

Fred Hutchinson Cancer Center, Immunotherapy Integrated Research Center, 2021, Physician Scholar

Fred Hutchinson Cancer Center, Clinical Research Division, 2019, Post-Doctoral Research Fellow

University of São Paulo School of Medicine, 2012, Hematopoietic Cell Transplantation Fellowship

University of São Paulo School of Medicine, 2011, Hematology and Transfusion Medicine Fellowship

University of São Paulo School of Medicine, 2009, Internal Medicine Residency

University of Brasília, 2006, MD

Research Interests

Leverage state-of-the-art technologies in order to gain a comprehensive understanding of the factors impacting outcomes following immunotherapies, such as CD19-targeted chimeric antigen receptor-modified T (CD19 CAR-T) cell therapy.

Aiming to translate these insights into enhanced therapeutic approaches, ultimately leading to improved patient outcomes.